John Thomas Biography and Net Worth

Director of Genelux

Dr. Thomas is a cofounder of Genelux Corporation and has been a member of the Board of Directors since August 2002. He was the company’s first Chief Financial Officer before leaving the post in 2004.

Professor Thomas serves as Dean, and is Bashir Hasso Professor of Entrepreneurship and Political Economy, of the School of Business and Management at La Sierra University. John has served on the board of ICON Business Bank since 2023 and is the audit committee chair. He has served on the board of ADRA International since September 2015; the Small Business Development Corporation of Orange County since 2016; and the TransResearch Consortium since 2000.

Professor Thomas holds MBA degrees in finance and marketing from Loma Linda University and Pune University; an M.A. in political economy, and a Ph.D. in economics and politics from Claremont Graduate University.

What is John Thomas' net worth?: The estimated net worth of John Thomas is at least $1.36 million as of June 1st, 2026. Mr. Thomas owns 472,784 shares of Genelux stock worth more than $1,361,618 as of August 27th. This net worth approximation does not reflect any other investments that Mr. Thomas may own. Learn More about John Thomas' net worth.
How do I contact John Thomas?: The corporate mailing address for Mr. Thomas and other Genelux executives is 2625 Townsgate Road Suite 230, Westlake Village CA, 91361. Genelux can also be reached via phone at 805-267-9889 and via email at [email protected]. Learn More on John Thomas' contact information.
Has John Thomas been buying or selling shares of Genelux?: John Thomas has not been actively trading shares of Genelux within the last three months. Most recently, John Thomas sold 10,000 shares of the business's stock in a transaction on Monday, June 1st. The shares were sold at an average price of $2.98, for a transaction totalling $29,800.00. Following the completion of the sale, the director now directly owns 472,784 shares of the company's stock, valued at $1,408,896.32. Learn More on John Thomas' trading history.
Who are Genelux's active insiders?: Genelux's insider roster includes John Thomas (Director), and James Tyree (Director). Learn More on Genelux's active insiders.
Are insiders buying or selling shares of Genelux?: In the last year, insiders at the sold shares 15 times. They sold a total of 56,111 shares worth more than $199,950.70. The most recent insider tranaction occured on August, 4th when insider Yong Yu sold 653 shares worth more than $1,919.82. Insiders at Genelux own 7.5% of the company. Learn More about insider trades at Genelux.
Information on this page was last updated on 8/4/2026.

John Thomas Insider Trading History at Genelux

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/1/2026	Sell	10,000	$2.98	$29,800.00	472,784
3/2/2026	Sell	10,000	$2.90	$29,000.00	482,784
12/1/2025	Sell	10,000	$5.00	$50,000.00	492,784
12/13/2023	Sell	9,000	$13.38	$120,420.00	463,460
10/16/2023	Sell	3,333	$20.71	$69,026.43	472,460
9/18/2023	Sell	3,334	$24.99	$83,316.66	475,793
9/15/2023	Sell	3,333	$21.90	$72,992.70	479,127

John Thomas Buying and Selling Activity at Genelux

Genelux Company Overview

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Today's Range

Now: $2.88

$2.72

$2.95

50 Day Range

MA: $2.85

$2.51

$3.05

2 Week Range

Now: $2.88

$2.29

$8.53

Volume

592,424 shs

Average Volume

232,765 shs

Market Capitalization

$130.29 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6